EXAS vs RCL · rev $2.76B vs P/E 26, rev $9.28B
EXACT Sciences Corporation (EXAS) versus Royal Caribbean Cruises Ltd (RCL) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Royal Caribbean Cruises Ltd (RCL) is a travel services company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported RCL revenue for 2026-06-30 was $9.28B. Net income was $2.07B. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
EXAS currently screens at market cap $20.03B. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
Not investment advice. Open the EXAS and RCL stock pages for the full models.
Not investment advice.